Sugi Predict

Sugi Predict / Compounds / SCHEMBL540925

SCHEMBL540925

SCHEMBL540925

NC(=O)C(O)C(N)Cc1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A4 P31645 1/20 0.52
▸ SLC6A2 P23975 1/20 0.48
▸ SLC6A3 Q01959 1/20 0.48
▸ CYP2C9 P11712 2/20 0.44
▸ CYP2C19 P33261 2/20 0.44
▸ PPARG P37231 1/20 0.42
▸ PPARA Q07869 1/20 0.42
▸ LAP3 P28838 3/20 0.41
▸ LTA4H P09960 2/20 0.41
▸ CTSC P53634 1/20 0.40
▸ DPP4 P27487 2/20 0.40
▸ DPP7 Q9UHL4 1/20 0.40
▸ ANPEP P15144 1/20 0.39
▸ RNPEP Q9H4A4 1/20 0.39
▸ DNPEP Q9ULA0 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ PYGL P06737 1/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5812524 0.87 SLC6A4 (0.53) SLC6A4SLC6A2SLC6A3CYP2C9CYP2C19
SCHEMBL6357746 0.87 SLC6A4 (0.53) SLC6A4SLC6A2SLC6A3CYP2C9CYP2C19
SCHEMBL7962713 0.84 SLC6A2 (0.52) SLC6A4SLC6A2SLC6A3CYP2C9CYP2C19
SCHEMBL22897282 0.82 EPHX1 (0.43) LAP3LTA4HANPEPRNPEPDNPEP
SCHEMBL22886776 0.82 TRPA1 (0.44) LAP3LTA4HDPP4DPP7ANPEP
SCHEMBL20028144 0.82 TRPA1 (0.44) LAP3LTA4HDPP4DPP7ANPEP
SCHEMBL6342154 0.81 SLC15A1 (0.56) LAP3LTA4HANPEPRNPEPDNPEP
SCHEMBL289159 0.81 SLC15A1 (0.56) LAP3LTA4HANPEPRNPEPDNPEP
SCHEMBL4619659 0.81 SLC15A1 (0.56) LAP3LTA4HANPEPRNPEPDNPEP
SCHEMBL10772763 0.81 SLC15A1 (0.56) LAP3LTA4HANPEPRNPEPDNPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220347173-A1 METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS BLADE THERAPEUTICS INC (US) 2022-11-03 — — US disclosed
EP-3820864-A1 METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS Blade Therapeutics, Inc. (US) 2021-05-19 — — EP disclosed
CN-112703188-A Method for treating liver fibrosis using calpain inhibitor 布莱德治疗公司 2021-04-23 — — CN disclosed
EP-3774737-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF Blade Therapeutics, Inc. (US) 2021-02-17 — — EP disclosed
US-20210009564-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPERTICS INC (US) 2021-01-14 — — US disclosed
US-20210009564-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPERTICS INC (US) 2021-01-14 — — US disclosed
CN-112204014-A Calpain modulators and therapeutic uses thereof 布莱德治疗公司 2021-01-08 — — CN disclosed
WO-2019190885-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. (US) 2019-10-03 — — WO disclosed
US-9139557-B2 Carboxamide compounds and their use as calpain inhibitors AbbVie Deutschland GmbH & Co. KG (DE) 2015-09-22 — — US disclosed
US-20130245003-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS ABBOTT GMBH & CO. KG (DE) 2013-09-19 — — US disclosed
US-8436034-B2 Carboxamide compounds and their use as calpain inhibitors ABBOTT GMBH & CO. KG (DE) 2013-05-07 — — US disclosed
EP-2121653-B1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS ABBOTT GMBH & CO KG (DE) 2012-02-08 — — EP disclosed
US-20100298326-A1 Carboxamide compounds and their use as calpain inhibitors ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2010-11-25 — — US disclosed
US-7799809-B2 Carboxamide compounds and their use as calpain inhibitors ABBOTT GMBH & CO. KG (DE) 2010-09-21 — — US disclosed
US-7728012-B2 Carboxamide compounds and their use as calpain inhibitors ABBOTT GMBH & CO. KG (DE) 2010-06-01 — — US disclosed
EP-2121653-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS Abbott GmbH & Co. KG (DE) 2009-11-25 — — EP disclosed
US-20080234329-A1 Carboxamide compounds and their use as calpain inhibitors ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-09-25 — — US disclosed
US-20080234330-A1 Carboxamide compounds and their use as calpain inhibitors ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-09-25 — — US disclosed
WO-2008080969-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS ABBOTT GMBH & CO. KG (DE) 2008-07-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298326-A1 Carboxamide compounds and their use as calpain inhibitors CAMK2A, CAPN2, CAPN1 SLC6A4 2513/4885SLC6A2 3431/4885SLC6A3 2853/4885
US-20220347173-A1 METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS CAPNS1, CAPN9, CAPN2 SLC6A4 4276/4885SLC6A2 4593/4885SLC6A3 4747/4885
US-20210009564-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF CAPNS1, CAPN9, CAPN1 SLC6A4 4564/4885SLC6A2 4741/4885SLC6A3 4655/4885
US-20080234329-A1 Carboxamide compounds and their use as calpain inhibitors CAMK2A, CAPN2, CAPN1 SLC6A4 2513/4885SLC6A2 3431/4885SLC6A3 2853/4885
US-20080234330-A1 Carboxamide compounds and their use as calpain inhibitors CAMK2A, CAPN2, CAPN1 SLC6A4 2513/4885SLC6A2 3431/4885SLC6A3 2853/4885
US-20130245003-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS CAMK2A, CAPN2, CAPN1 SLC6A4 2513/4885SLC6A2 3431/4885SLC6A3 2853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.